← Human Trials & Peer-Reviewed Studies
Energy deprivation alters in a leptin- and cortisol-independent manner circulating levels of activin A and follistatin but not myostatin in healthy males.
Plain-language guide to PMID 21865351 (2011): double-blind randomized controlled trial of Follistatin-344.
Key Facts
- PMID
- 21865351
- Journal
- The Journal of clinical endocrinology and metabolism
- Year
- 2011
- Study type
- Randomized Controlled Trial
- Authors
- Vamvini MT et al. (4 authors)
- DOI
- 10.1210/jc.2011-1665
What This Study Did, in Plain Language
What Was Tested
The paper reports a study of Follistatin-344, published as a randomized controlled trial.
The objective of the study was to explore day/night patterns of secretion and assess whether energy deprivation alters circulating levels of activin A, myostatin, follistatin, and cortisol and to examine whether leptin may mediate this effect.
The two fasting studies were randomized and double blinded.
Blood samples were obtained every 15 min from 0800 h on d 3 until 0800 h on d 4 and pooled hourly.
Why It Was Studied
Activin A, myostatin, and follistatin have recently emerged as important regulatory molecules of reproduction and the musculoskeletal system.
Little is known, however, about their day/night patterns of secretion and their physiological regulation by energy availability.
Who Took Part
PubMed indexes the participants as adults, men only.
How the Study Was Run
In design terms this was a randomized, double-blind and placebo-controlled study.
Random assignment meant chance, not the researchers, decided who got Follistatin-344 and who got the comparison, which limits bias.
As a double-blind Follistatin-344 study, the assignments were hidden from both participants and investigators until the end.
Some participants received a placebo instead of Follistatin-344, giving a reference point.
What Was Measured
PubMed files the paper under topics including Activins, Body Mass Index, Follistatin, Food Deprivation, Hydrocortisone, Leptin and Myostatin.
What This Means in Plain Language
The paper is a randomized, double-blind and placebo-controlled study of Follistatin-344.
Results are reported in around 8 sentences of the abstract; we leave them to the paper itself rather than summarise them.
The publication is from 2011 (The Journal of clinical endocrinology and metabolism), a journal based in United States.
More context: the Follistatin-344 compound page, all human trials.
Our Notes on the Compound
Follistatin-344: A myostatin- and activin-binding protein studied in gene-therapy trials for muscular dystrophy; black-market vials have been found mislabeled.
Related Pages
Source: PubMed record. This explanation is written by PeptideWhiz from the public record. For research and education only. Not medical advice; no dosing information is given.